Enliven Therapeutics has decided against taking its phase 1-stage solid tumor drug into further development next year in ...

England’s drug approval body has resisted pressure from pharmaceutical companies to loosen its process for recommending drugs and is pressing instead for the NHS to speed up the rollout of approved ...

AstraZeneca has a target of $5 billion or more in peak annual sales for both Enhertu and Datroway, making the pair a core part of its objective of achieving $80 billion in group revenues by 2030.

Daiichi Sankyo has been ordered to pay an 8% royalty rate on sales of AstraZeneca-partnered breast and gastric cancer therapy Enhertu (trastuzumab deruxtecan) after Seagen won a lawsuit claiming ...

Positive results from the DESTINY-Breast11 Phase III trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), when ...